In silico Screening and Behavioral Validation of a Novel Peptide, LCGA-17, With Anxiolytic-Like Properties

In silico Screening and Behavioral Validation of a Novel Peptide, LCGA-17, With Anxiolytic-Like Properties

The aim of the study was to develop better anxiolytics and antidepressants. We focused on GABAA receptors and the α2δ auxiliary subunit of V-gated Ca2+ channels as putative targets because they are established as mediators of efficacious anxiolytics, antidepressants, and anticonvulsants. We further...

Full description

Bibliographic Details
Main Authors: Anton V. Malyshev, Iuliia A. Sukhanova, Alexander S. Zlobin, Vasilina R. Gedzun, Vsevolod V. Pavshintsev, Ekaterina V. Vasileva, Arthur O. Zalevsky, Igor I. Doronin, Nikita A. Mitkin, Andrey V. Golovin, Maxim L. Lovat, Georgy I. Kovalev, Yurii A. Zolotarev, Askar R. Kuchumov, Gennady A. Babkin, Bernhard Luscher
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Neuroscience
Subjects:
peptide drugs
drug screening
novel ligand
NMDA receptor
alpha(2)delta subunit
computational approach
Online Access:https://www.frontiersin.org/articles/10.3389/fnins.2021.705590/full

Internet

https://www.frontiersin.org/articles/10.3389/fnins.2021.705590/full

Similar Items